NL301096I2 - Filgotinib of een zout daarvan - Google Patents

Filgotinib of een zout daarvan Download PDF

Info

Publication number: NL301096I2
Authority: NL; Netherlands
Prior art keywords: filgotinib; salt
Prior art date: 2009-06-26

Application number

NL301096C

Other languages

English (en)

Other versions

NL301096I1 (nl

Original Assignee

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-26

Filing date

2021-03-17

Publication date

2021-04-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301096(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-03-17 Application filed by Galapagos Nv filed Critical Galapagos Nv

2021-03-24 Publication of NL301096I1 publication Critical patent/NL301096I1/nl

2021-04-12 Publication of NL301096I2 publication Critical patent/NL301096I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL301096C 2009-06-26 2021-03-17 Filgotinib of een zout daarvan NL301096I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22068809P	2009-06-26	2009-06-26
PCT/EP2010/059064 WO2010149769A1 (en)	2009-06-26	2010-06-25	5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Publications (2)

Publication Number	Publication Date
NL301096I1 NL301096I1 (nl)	2021-03-24
NL301096I2 true NL301096I2 (nl)	2021-04-12

Family

ID=42562363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301096C NL301096I2 (nl)	2009-06-26	2021-03-17	Filgotinib of een zout daarvan

Country Status (43)

Country	Link
US (9)	US8088764B2 (nl)
EP (2)	EP2445911B1 (nl)
JP (2)	JP5591925B2 (nl)
KR (3)	KR101916194B1 (nl)
CN (2)	CN104262337A (nl)
AR (1)	AR077220A1 (nl)
AU (3)	AU2010264633B2 (nl)
BR (1)	BRPI1015569B8 (nl)
CA (1)	CA2765985C (nl)
CL (1)	CL2011003247A1 (nl)
CO (1)	CO6491040A2 (nl)
CR (1)	CR20120016A (nl)
CY (3)	CY1119214T1 (nl)
DK (2)	DK3178819T3 (nl)
DO (1)	DOP2011000388A (nl)
EA (1)	EA021637B1 (nl)
EC (1)	ECSP12011626A (nl)
ES (2)	ES2626908T3 (nl)
FR (1)	FR21C1011I2 (nl)
GB (1)	GB2483424B (nl)
HR (2)	HRP20170826T1 (nl)
HU (3)	HUE033154T2 (nl)
IL (1)	IL216667A (nl)
LT (3)	LT3178819T (nl)
MA (1)	MA33448B1 (nl)
ME (1)	ME02699B (nl)
MX (1)	MX344951B (nl)
MY (1)	MY156664A (nl)
NI (1)	NI201100222A (nl)
NL (1)	NL301096I2 (nl)
NO (1)	NO2021013I1 (nl)
NZ (1)	NZ596838A (nl)
PE (1)	PE20121032A1 (nl)
PL (2)	PL3178819T3 (nl)
PT (2)	PT2445911T (nl)
RS (1)	RS56035B1 (nl)
SG (2)	SG10201703497YA (nl)
SI (2)	SI3178819T1 (nl)
SM (1)	SMT201700265T1 (nl)
TW (1)	TWI462920B (nl)
UA (1)	UA107935C2 (nl)
WO (1)	WO2010149769A1 (nl)
ZA (1)	ZA201109386B (nl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
MX359879B (es)	2009-10-02	2018-10-12	Foamix Pharmaceuticals Ltd	Composiciones tópicas de tetraciclina.
EP2343294A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Substituted triazolopyridines
AR086042A1 (es) *	2011-04-28	2013-11-13	Galapagos Nv	Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
EP2770992A4 (en) *	2011-10-26	2015-12-30	Emily A Stein	AGENTS, METHODS AND DEVICES FOR AFFECTING NERVOUS FUNCTION
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
PE20150187A1 (es) *	2012-06-22	2015-02-27	Galapagos Nv	Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma
GB201302036D0 (en) *	2013-02-05	2013-03-20	Queen Mary & Westfield College	Diagnosis
JP2016540009A (ja) *	2013-12-11	2016-12-22	セファロンインコーポレイテッド	１，２，４‐トリアゾロ［１，５ａ］ピリジン誘導体を用いた多発性硬化症の処置
GB201402071D0 (en) *	2014-02-07	2014-03-26	Galapagos Nv	Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
TWI679205B (zh)	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
KR102747428B1 (ko)	2015-04-13	2024-12-27	알파시그마 에스.피.에이.	심혈관 질환의 치료 방법
WO2016165953A1 (en)	2015-04-13	2016-10-20	Galapagos Nv	Methods for the treatment of inflammatory disorders
WO2016179207A1 (en) *	2015-05-05	2016-11-10	Concert Pharmaceuticals, Inc.	Deuterated filgotinib
CN105061420B (zh) *	2015-06-04	2017-09-05	南京旗昌医药科技有限公司	一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) *	2015-07-14	2017-01-11	苏州富士莱医药股份有限公司	一种Filgotinib的合成方法
WO2017012771A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Crystalline filgotinib sulfonic acid addition salts
WO2017012770A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Acid addition salts of filgotinib
WO2017012773A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Solid forms of filgotinib free base
CN105218539B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198880B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198879B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198876B (zh) *	2015-09-18	2017-09-29	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198878B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105111207B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105111206B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物e晶型及其制备方法
US20170174788A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017106564A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) *	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017133423A1 (zh) *	2016-02-02	2017-08-10	深圳市塔吉瑞生物医药有限公司	一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh)	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
CN105669669A (zh) *	2016-03-04	2016-06-15	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
CN109071531A (zh) *	2016-03-21	2018-12-21	苏州晶云药物科技股份有限公司	用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
US10071079B2 (en) *	2016-06-29	2018-09-11	Bristol-Myers Squibb Company	[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
US11414413B2 (en)	2016-07-26	2022-08-16	Suzhou Longbiotech Pharmaceuticals Co., Ltd.	Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof
AU2017307208B2 (en)	2016-07-30	2021-01-21	Bristol-Myers Squibb Company	Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
CN107759587B (zh) *	2016-08-19	2021-01-26	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA2978573A1 (en)	2016-09-08	2018-03-08	Foamix Pharmaceuticals Ltd.	Compositions and methods for treating rosacea and acne
JP7028861B2 (ja)	2016-09-09	2022-03-02	ブリストル－マイヤーズスクイブカンパニー	ピリジル置換のインドール化合物
CN107880038B (zh) *	2016-09-30	2021-09-28	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
US20190314382A1 (en)	2016-11-10	2019-10-17	Galapagos Nv	Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039344B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en)	2017-02-17	2017-04-05	Galápagos Nv	Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar)	2017-03-14	2019-01-30	Gilead Sciences Inc	تركيبات صيدلية تتضمن مثبط jak
JP7104775B2 (ja)	2017-08-04	2022-07-21	ブリストル－マイヤーズスクイブカンパニー	Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
EP3661934B1 (en)	2017-08-04	2022-06-01	Bristol-Myers Squibb Company	[1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds
EP3710440B1 (en)	2017-11-14	2023-04-05	Bristol-Myers Squibb Company	Substituted indole compounds
SG11202005513TA (en)	2017-12-15	2020-07-29	Bristol Myers Squibb Co	Substituted indole ether compounds
HRP20231244T1 (hr)	2017-12-18	2024-02-16	Bristol-Myers Squibb Company	Spoj 4-azaindola
AU2018392316B2 (en)	2017-12-19	2022-05-12	Bristol-Myers Squibb Company	Amide substituted indole compounds useful as TLR inhibitors
AU2018390820A1 (en)	2017-12-19	2020-08-06	Bristol-Myers Squibb Company	Substituted indole compounds useful as TLR inhibitors
CN111699185B (zh)	2017-12-19	2023-06-27	百时美施贵宝公司	6-氮杂吲哚化合物
JP7382938B2 (ja)	2017-12-20	2023-11-17	ブリストル－マイヤーズスクイブカンパニー	ジアザインドール化合物
JP7291707B2 (ja)	2017-12-20	2023-06-15	ブリストル－マイヤーズスクイブカンパニー	アリールおよびヘテロアリール置換されたインドール化合物
KR102714788B1 (ko)	2017-12-20	2024-10-08	브리스톨-마이어스 스큅 컴퍼니	Tlr 억제제로서 유용한 아미노 인돌 화합물
GB201808575D0 (en) *	2018-05-24	2018-07-11	Galapagos Nv	Methods for the treatment of psoriatic arthrits
US10815227B2 (en)	2018-08-27	2020-10-27	Cadila Healthcare Limited	Processes for the preparation of filgotinib
WO2020086503A1 (en)	2018-10-24	2020-04-30	Bristol-Myers Squibb Company	Substituted indole and indazole compounds
JP7597710B2 (ja)	2018-10-24	2024-12-10	ブリストル－マイヤーズスクイブカンパニー	置換インドール二量体の化合物
CN115029299B (zh) *	2018-11-07	2023-11-14	杭州瑞普晨创科技有限公司	JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) *	2019-03-05	2020-09-10	苏州科睿思制药有限公司	Filgotinib的马来酸盐晶型CSI及其制备方法和用途
KR102737181B1 (ko)	2019-03-14	2024-12-02	상하이 시너지 파마슈티컬 사이언시스 코., 엘티디.	Jak 억제제 및 그 제조방법과 의약분야에서의 응용
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3947381A4 (en)	2019-03-30	2024-07-24	Unichem Laboratories Ltd	Novel process for the preparation of filgotinib and intermediates thereof
ES2987832T3 (es)	2019-05-09	2024-11-18	Bristol Myers Squibb Co	Compuestos de benzimidazolona sustituidos
CN110204542B (zh) *	2019-05-23	2022-05-20	四川伊诺达博医药科技有限公司	一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) *	2019-06-03	2019-08-23	上海基科生物化学有限公司	一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
WO2021067326A1 (en)	2019-10-01	2021-04-08	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
US12384760B2 (en)	2019-10-04	2025-08-12	Bristol-Myers Squibb Company	Substituted carbazole compounds
IT201900020240A1 (it)	2019-11-04	2021-05-04	Advitech Advisory And Tech Sa	Procedimento per la preparazione di Filgotinib e intermedi di sintesi
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN110878097B (zh) *	2019-11-29	2021-11-02	杭州科巢生物科技有限公司	菲格替尼的制备方法
CN111072655B (zh) *	2019-12-30	2021-12-10	深圳市坤健创新药物研究院	一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
EP4105214A4 (en) *	2020-02-13	2023-11-08	Zhuhai United Laboratories Co., Ltd.	USE OF JAK KINASE INHIBITORS IN THE PREPARATION OF DRUGS FOR TREATING DISEASES ASSOCIATED WITH JAK KINASE
ES3037893T3 (en)	2020-02-21	2025-10-07	Zhuhai United Laboratories Co Ltd	Crystalline form of jak inhibitor and application thereof
EP4196477A4 (en) *	2020-08-17	2024-10-09	Vyne Therapeutics Inc.	TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS
US20230355608A1 (en) *	2020-10-02	2023-11-09	University Of Massachusetts	Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) *	2021-05-19	2022-11-22	奥锐特药业(天津)有限公司	一种Filgotinib中间体的制备方法
CN113773322B (zh) *	2021-11-10	2022-02-11	奥锐特药业(天津)有限公司	一种Filgotinib的制备方法
CN114409675B (zh) *	2022-01-07	2023-08-04	重庆医科大学	螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) *	2022-01-18	2023-07-28	盛世泰科生物医药技术(苏州)有限公司	一种含环丙酰胺化合物及其应用
WO2023194842A1 (en)	2022-04-05	2023-10-12	Unichem Laboratories Limited	Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ208996A (en)	1983-07-28	1989-08-29	American Cyanamid Co	5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
DE60016384T2 (de)	1999-01-29	2005-12-01	Chugai Seiyaku K.K.	Chondrogonese promotoren und indolin-2-on derivate
EP1391211A1 (en)	2001-04-27	2004-02-25	Chugai Seiyaku Kabushiki Kaisha	Chondrogenesis promoters
US6514989B1 (en) *	2001-07-20	2003-02-04	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
BRPI0407384A (pt)	2003-02-14	2006-02-21	Pfizer Prod Inc	piridinas-triazóis como compostos antiinflamatórios
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
EP2360474B1 (en)	2004-06-21	2013-07-24	Galapagos N.V.	Methods and means for treatment of osteoarthritis
WO2006018735A2 (en)	2004-08-18	2006-02-23	Pharmacia & Upjohn Company Llc	Triazolopyridine compounds
MX2007004179A (es)	2004-10-07	2007-06-07	Warner Lambert Co	Derivados de triazolpiridina como agentes antibacterianos.
GB0515026D0 (en)	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
BRPI0716239A2 (pt)	2006-08-30	2013-08-13	Cellzome Ltd	derivados de triazol como inibidores de cinase
TW200904816A (en)	2007-06-05	2009-02-01	Takeda Pharmaceutical	Fused heterocycle derivatives and use thereof
EP2178868A1 (en)	2007-07-18	2010-04-28	Novartis Ag	Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) *	2007-08-01	2009-02-05	Phenomix Corporation	Inhibitors of jak2 kinase
MX2010002312A (es)	2007-08-31	2010-03-18	Merck Serono Sa	Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) *	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
PE20110063A1 (es)	2008-06-20	2011-02-16	Genentech Inc	DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
CA2727036C (en)	2008-06-20	2017-03-21	Genentech, Inc.	Triazolopyridine jak inhibitor compounds and methods
WO2010010189A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) *	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010188A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010141796A2 (en)	2009-06-05	2010-12-09	Cephalon, Inc.	PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
PE20150187A1 (es)	2012-06-22	2015-02-27	Galapagos Nv	Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma

2010
- 2010-06-23 TW TW099120586A patent/TWI462920B/zh active
- 2010-06-24 AR ARP100102235A patent/AR077220A1/es active IP Right Grant
- 2010-06-25 LT LTEP17152084.4T patent/LT3178819T/lt unknown
- 2010-06-25 AU AU2010264633A patent/AU2010264633B2/en active Active
- 2010-06-25 CN CN201410408911.8A patent/CN104262337A/zh active Pending
- 2010-06-25 PT PT107248817T patent/PT2445911T/pt unknown
- 2010-06-25 GB GB1200457.8A patent/GB2483424B/en not_active Expired - Fee Related
- 2010-06-25 SI SI201031962T patent/SI3178819T1/sl unknown
- 2010-06-25 HR HRP20170826TT patent/HRP20170826T1/hr unknown
- 2010-06-25 RS RS20170532A patent/RS56035B1/sr unknown
- 2010-06-25 PL PL17152084T patent/PL3178819T3/pl unknown
- 2010-06-25 NZ NZ596838A patent/NZ596838A/en unknown
- 2010-06-25 LT LTEP10724881.7T patent/LT2445911T/lt unknown
- 2010-06-25 HU HUE10724881A patent/HUE033154T2/en unknown
- 2010-06-25 KR KR1020187010516A patent/KR101916194B1/ko active Active
- 2010-06-25 ME MEP-2017-122A patent/ME02699B/me unknown
- 2010-06-25 PE PE2011002153A patent/PE20121032A1/es active IP Right Grant
- 2010-06-25 US US12/823,654 patent/US8088764B2/en active Active
- 2010-06-25 PT PT171520844T patent/PT3178819T/pt unknown
- 2010-06-25 PL PL10724881T patent/PL2445911T3/pl unknown
- 2010-06-25 MX MX2011013450A patent/MX344951B/es active IP Right Grant
- 2010-06-25 SG SG10201703497YA patent/SG10201703497YA/en unknown
- 2010-06-25 MA MA34556A patent/MA33448B1/fr unknown
- 2010-06-25 EP EP10724881.7A patent/EP2445911B1/en active Active
- 2010-06-25 JP JP2012516761A patent/JP5591925B2/ja active Active
- 2010-06-25 ES ES10724881.7T patent/ES2626908T3/es active Active
- 2010-06-25 UA UAA201200745A patent/UA107935C2/ru unknown
- 2010-06-25 ES ES17152084T patent/ES2766573T3/es active Active
- 2010-06-25 HU HUE17152084A patent/HUE047478T2/hu unknown
- 2010-06-25 MY MYPI2011006263A patent/MY156664A/en unknown
- 2010-06-25 DK DK17152084.4T patent/DK3178819T3/da active
- 2010-06-25 KR KR1020127001940A patent/KR101696669B1/ko active Active
- 2010-06-25 BR BRPI1015569A patent/BRPI1015569B8/pt active IP Right Grant
- 2010-06-25 SG SG2011096211A patent/SG177363A1/en unknown
- 2010-06-25 SI SI201031467A patent/SI2445911T1/sl unknown
- 2010-06-25 KR KR1020177000585A patent/KR101850716B1/ko active Active
- 2010-06-25 SM SM20170265T patent/SMT201700265T1/it unknown
- 2010-06-25 EP EP17152084.4A patent/EP3178819B1/en active Active
- 2010-06-25 CA CA2765985A patent/CA2765985C/en active Active
- 2010-06-25 WO PCT/EP2010/059064 patent/WO2010149769A1/en not_active Ceased
- 2010-06-25 DK DK10724881.7T patent/DK2445911T3/en active
- 2010-06-25 CN CN201080028631.4A patent/CN102482273B/zh active Active
- 2010-06-25 EA EA201270075A patent/EA021637B1/ru unknown
2011
- 2011-11-29 IL IL216667A patent/IL216667A/en active IP Right Grant
- 2011-12-02 US US13/310,090 patent/US8563545B2/en active Active
- 2011-12-14 DO DO2011000388A patent/DOP2011000388A/es unknown
- 2011-12-20 ZA ZA2011/09386A patent/ZA201109386B/en unknown
- 2011-12-21 CL CL2011003247A patent/CL2011003247A1/es unknown
- 2011-12-21 NI NI201100222A patent/NI201100222A/es unknown
2012
- 2012-01-11 CR CR20120016A patent/CR20120016A/es unknown
- 2012-01-16 CO CO12005379A patent/CO6491040A2/es active IP Right Grant
- 2012-01-26 EC EC2012011626A patent/ECSP12011626A/es unknown
2013
- 2013-09-13 US US14/026,027 patent/US8999979B2/en active Active
2014
- 2014-07-30 JP JP2014154379A patent/JP2014221825A/ja not_active Withdrawn
2015
- 2015-04-02 US US14/677,058 patent/US9309244B2/en active Active
- 2015-08-28 AU AU2015218544A patent/AU2015218544B2/en active Active
2016
- 2016-04-11 US US15/095,317 patent/US9707237B2/en active Active
2017
- 2017-05-31 CY CY20171100569T patent/CY1119214T1/el unknown
- 2017-07-10 AU AU2017204744A patent/AU2017204744A1/en not_active Abandoned
- 2017-07-17 US US15/651,116 patent/US10328081B2/en active Active
2019
- 2019-05-09 US US16/407,593 patent/US11000528B2/en active Active
2020
- 2020-01-09 HR HRP20200033TT patent/HRP20200033T1/hr unknown
- 2020-01-09 CY CY20201100020T patent/CY1122649T1/el unknown
2021
- 2021-03-03 FR FR21C1011C patent/FR21C1011I2/fr active Active
- 2021-03-04 HU HUS2100007C patent/HUS2100007I1/hu unknown
- 2021-03-17 NL NL301096C patent/NL301096I2/nl unknown
- 2021-03-19 LT LTPA2021504C patent/LTC2445911I2/lt unknown
- 2021-03-23 NO NO2021013C patent/NO2021013I1/no unknown
- 2021-03-29 CY CY2008021C patent/CY2021008I2/el unknown
- 2021-04-14 US US17/230,483 patent/US12042498B2/en active Active
2024
- 2024-06-13 US US18/741,974 patent/US20240325405A1/en active Pending

Also Published As

Publication number	Publication date
US20160296530A1 (en)	2016-10-13
GB2483424B (en)	2012-07-18
EP3178819A1 (en)	2017-06-14
AU2015218544B2 (en)	2017-04-27
US20200078365A1 (en)	2020-03-12
KR20120107919A (ko)	2012-10-04
MY156664A (en)	2016-03-15
GB201200457D0 (en)	2012-02-22
UA107935C2 (xx)	2015-03-10
IL216667A (en)	2015-08-31
JP2014221825A (ja)	2014-11-27
GB2483424A (en)	2012-03-07
SG177363A1 (en)	2012-02-28
AU2015218544A1 (en)	2015-09-17
US20140100220A1 (en)	2014-04-10
RS56035B1 (sr)	2017-09-29
KR20180041262A (ko)	2018-04-23
HUS2100007I1 (hu)	2021-03-29
US20120142678A1 (en)	2012-06-07
PT3178819T (pt)	2020-01-21
ECSP12011626A (es)	2012-02-29
US9309244B2 (en)	2016-04-12
US8999979B2 (en)	2015-04-07
AU2010264633A1 (en)	2011-12-22
BRPI1015569B8 (pt)	2021-05-25
US20100331319A1 (en)	2010-12-30
ZA201109386B (en)	2012-08-29
LT3178819T (lt)	2020-01-27
HRP20200033T1 (hr)	2020-03-20
CY1119214T1 (el)	2018-02-14
EP2445911B1 (en)	2017-03-01
US8088764B2 (en)	2012-01-03
AR077220A1 (es)	2011-08-10
JP2012530766A (ja)	2012-12-06
NZ596838A (en)	2014-01-31
EP2445911A1 (en)	2012-05-02
US11000528B2 (en)	2021-05-11
SMT201700265T1 (it)	2017-07-18
CR20120016A (es)	2012-02-09
US9707237B2 (en)	2017-07-18
ME02699B (me)	2017-10-20
CY2021008I1 (el)	2021-05-05
NI201100222A (es)	2012-07-27
KR20170007534A (ko)	2017-01-18
FR21C1011I1 (nl)	2021-05-07
LTC2445911I2 (lt)	2022-09-26
US20210369727A1 (en)	2021-12-02
NL301096I1 (nl)	2021-03-24
MX2011013450A (es)	2012-05-08
WO2010149769A1 (en)	2010-12-29
LTPA2021504I1 (lt)	2021-04-12
HK1167403A1 (en)	2012-11-30
US20180000831A1 (en)	2018-01-04
SG10201703497YA (en)	2017-06-29
FR21C1011I2 (fr)	2022-03-25
IL216667A0 (en)	2012-02-29
MA33448B1 (fr)	2012-07-03
JP5591925B2 (ja)	2014-09-17
NO2021013I1 (no)	2021-03-23
KR101916194B1 (ko)	2018-11-07
CY2021008I2 (el)	2021-06-25
EP3178819B1 (en)	2019-12-04
AU2017204744A1 (en)	2017-07-27
US12042498B2 (en)	2024-07-23
CN104262337A (zh)	2015-01-07
PL2445911T3 (pl)	2017-08-31
BRPI1015569B1 (pt)	2020-10-27
CN102482273B (zh)	2014-09-17
HUE047478T2 (hu)	2020-04-28
ES2766573T3 (es)	2020-06-12
DK3178819T3 (en)	2020-01-27
CL2011003247A1 (es)	2012-04-13
US20240325405A1 (en)	2024-10-03
EA021637B1 (ru)	2015-07-30
AU2010264633B2 (en)	2015-06-04
BRPI1015569A2 (pt)	2016-08-16
US8563545B2 (en)	2013-10-22
DOP2011000388A (es)	2012-04-15
CO6491040A2 (es)	2012-07-31
HRP20170826T1 (hr)	2017-08-25
US10328081B2 (en)	2019-06-25
CN102482273A (zh)	2012-05-30
DK2445911T3 (en)	2017-06-06
SI2445911T1 (sl)	2017-07-31
KR101696669B1 (ko)	2017-01-16
US20150274722A1 (en)	2015-10-01
TW201103936A (en)	2011-02-01
PL3178819T3 (pl)	2020-04-30
HUE033154T2 (en)	2017-11-28
PT2445911T (pt)	2017-06-12
SI3178819T1 (sl)	2020-02-28
CA2765985C (en)	2017-06-06
MX344951B (es)	2017-01-12
CA2765985A1 (en)	2010-12-29
EA201270075A1 (ru)	2012-12-28
PE20121032A1 (es)	2012-08-25
TWI462920B (zh)	2014-12-01
LT2445911T (lt)	2017-06-12
KR101850716B1 (ko)	2018-04-20
CY1122649T1 (el)	2021-03-12
ES2626908T3 (es)	2017-07-26

Publication	Publication Date	Title
NL301096I2 (nl)	2021-04-12	Filgotinib of een zout daarvan
NL301028I2 (nl)	2020-04-15	Gilteritinib of een zout ervan
NL301071I1 (nl)	2020-11-11	Alpelisib of een zout ervan
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL300963I2 (nl)	2021-03-08	inotersen of een zout daarvan
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301035I1 (nl)	2020-03-25	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301254I2 (nl)	2024-01-10	Futibatinib of een zout daarvan
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL300876I2 (nl)	2017-07-11	Alectinib dan wel een zout of solvaat daarvan
IL257693B (en)	2019-12-31	Fungicidal compositions
NL300900I2 (nl)	2017-11-16	glecaprevir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
EP2501753A4 (en)	2014-01-22	STRONG NANOPAPER
EP2622917A4 (en)	2014-07-09	POSITIONING
EP2400987A4 (en)	2012-08-22	COMPOSITIONS OF CYCLOPOLYSACCHARIDE AND BENDAMUSTIN
EP2622916A4 (en)	2014-07-09	POSITIONING
NO2023002I1 (no)	2023-01-05	Lasmiditan or a pharmaceutically acceptable salt thereof
DK2629865T3 (da)	2015-06-22	Legetøjsbyggesæt